Your Daily Pharma Scoop: Exelixis Still Attractive, Portola’s BevyxXa, Pluristem Patent
Your Daily Pharma Scoop: Exelixis Still Attractive, Portola’s BevyxXa, Pluristem Patent Seeking Alpha Full coverage
PATENT NEWS
-
In: PATENT NEWS
-
In: PATENT NEWS
First-Ever Patent Insurance Package that Covers the Entire Patent Life Cycle Offered Hits the Chinese Market
First-Ever Patent Insurance Package that Covers the Entire Patent Life Cycle Offered Hits the Chinese Market Lexology Full coverage
-
In: PATENT NEWS
BRIEF-Anhui Anke Biotechnology Group receives patent license
BRIEF-Anhui Anke Biotechnology Group receives patent license Reuters Full coverage
-
In: PATENT NEWS
European Patent Office Grants to ASIT biotech a Second Patent Related to the Active Ingredients Used in the ASIT+ …
European Patent Office Grants to ASIT biotech a Second Patent Related to the Active Ingredients Used in the ASIT+ … Business Wire (press release) Full coverage
-
In: PATENT NEWS
Illumina Gets Favorable Ruling in UK NIPT Patent Infringement Lawsuit
Illumina Gets Favorable Ruling in UK NIPT Patent Infringement Lawsuit GenomeWeb Full coverage
-
In: PATENT NEWS
Patent office boosts fees for filings and challenges
Patent office boosts fees for filings and challenges Chemical & Engineering News Full coverage
-
In: PATENT NEWS
How BlackBerry Is Looking To Better Monetize Its Patents
How BlackBerry Is Looking To Better Monetize Its Patents Forbes Full coverage
-
In: PATENT NEWS
ERS Genomics Provides Update on US Patent Interference Process
ERS Genomics Provides Update on US Patent Interference Process Business Wire (press release) Full coverage
-
In: PATENT NEWS
Pluristem granted key US patent for Skeletal Muscle Regeneration
Pluristem granted key US patent for Skeletal Muscle Regeneration Seeking Alpha Full coverage
-
In: PATENT NEWS
Pluristem Granted Key US Patent for Skeletal Muscle Regeneration – a Meaningful Asset Ahead of Upcoming Phase III …
Pluristem Granted Key US Patent for Skeletal Muscle Regeneration – a Meaningful Asset Ahead of Upcoming Phase III … GlobeNewswire (press release) Full coverage